Articles tagged with Bleeding
A new hand-held EEG device has been shown to accurately rule out brain bleeding in patients with head injuries. The device, approved by the FDA in 2016, can quickly assess electrical activity in the brain to determine if a patient needs further evaluation and treatment.
A new analysis found that apixaban, a non-vitamin K antagonist oral anticoagulant (NOAC), is superior to warfarin in reducing brain bleeds and stroke risk in patients with atrial fibrillation. The study showed that apixaban reduced intracranial hemorrhage by 58% compared to warfarin.
The CLUE Working Group conducted two systematic reviews to address thrombosis and hemorrhage risks after urological cancer operations and other forms of urological surgery. The studies found that anticoagulant prophylaxis is justified in high-risk patients, but not necessarily in low-risk procedures.
Researchers from UnityPoint Health developed an effective eight-minute educational module to teach staff in a large workplace about basic knowledge and skills to locate and use bleeding control equipment. The module showed positive results with 55% of respondents having direct patient care responsibilities, but limitations were noted r...
A Temple University Health System research team identified sex-based differences in the utilization and safety outcomes of catheter-directed thrombolysis (CDT) for treatment of deep vein thrombosis (DVT). Female patients were less likely to receive CDT, while males experienced more bleeding complications, but with similar mortality rates.
A recent study by researchers at the Medical University of South Carolina found that nasogastric tube placement in patients with typical upper GI bleeding had no impact on outcomes. The study's results suggest that this procedure may be unnecessary for millions of patients, reducing costs and discomfort associated with it.
A recent study found that uninterrupted treatment with dabigatran before, during, and after atrial fibrillation ablation significantly reduced the incidence of major bleeding events compared to warfarin. The trial showed a 5.3% reduction in major bleeding events, with major bleeds occurring in 1.6% of patients receiving dabigatran.
A Phase 2 study found that replacing aspirin with low-dose rivaroxaban in addition to an antiplatelet medication does not increase bleeding complications in patients with acute coronary syndrome. The study, which involved over 3,000 patients, suggests that this dual therapy approach may be a safe alternative to lifelong aspirin treatment.
A low-dose blood-thinning medication reduced VTE recurrences more than threefold compared to aspirin without increasing bleeding side effects, according to a large international study. The study's findings support the use of rivaroxaban as a safe and effective treatment option for patients at risk for recurrent VTE.
A large international study found that rivaroxaban is more effective and safer than aspirin at preventing recurrent blood clots. The study showed that patients taking rivaroxaban had significantly lower rates of recurrent clots compared to those taking aspirin.
A large community-based study found that antithrombotic therapy does not decrease stroke risk in low-risk atrial fibrillation patients, but rather increases the risk of significant bleeding and death. The study contradicts current standards and highlights the need for more research on optimal therapies for these patients.
A study of over 25,600 patients found that long-term dual antiplatelet therapy increases mortality risk, especially after bleeding events. Ischemic events also pose a significant threat to patient lives.
A clinical study demonstrates that microwave measurements can quickly detect intracranial bleeding in traumatic brain injuries. The technology has great potential to improve medical assessment and reduce waiting times for patients with head injuries.
A California study found that using maternal safety toolkits and collaborating across multiple healthcare organizations can effectively reduce obstetric hemorrhage, the leading cause of maternal death worldwide. The study showed a 21% reduction in severe hemorrhage after one year and a 28% reduction in smaller hospitals.
Researchers found that osteopathic structural examinations can help identify ectopic pregnancies, particularly those located outside the fallopian tubes. This technique is useful in emergency situations where imaging fails due to bleeding caused by a rupture.
Researchers with the California Maternal Quality Care Collaborative present a study showing that a state-wide perinatal collaborative can significantly reduce severe maternal morbidity from hemorrhage. The project involved 99 hospitals and resulted in a 21% reduction in severe hemorrhage after one year, with smaller hospitals showing t...
A new study published in Gastrointestinal Endoscopy found that capsule endoscopy can effectively rule out active upper GI bleeding or high-risk lesions in patients presenting with symptoms of possible UGIB. This reduces unnecessary hospital admissions and improves patient outcomes.
A recent study published in BMJ Global Health reveals that children from low-income countries are at a significantly higher risk of dying after emergency abdominal surgery. The likelihood of dying is up to 7 times greater than for children from rich nations.
Researchers reported the highest and most sustained levels of clotting factor IX in hemophilia B patients after a single dose of experimental gene therapy. Patients were able to discontinue factor infusions and engage in normal activities without disabling bleeding episodes, significantly improving their quality of life.
A new analysis found that restarting dabigatran after a major bleeding event leads to lower recurrent hemorrhage risk compared to warfarin. Resuming anticoagulation therapy also reduced the likelihood of stroke-free survival, with dabigatran associated with nearly half the risk of another major bleeding event within one year.
Researchers discovered that targeting the TGF-β1 pathway can reduce pro-inflammatory signals and improve motor function in mice after intracerebral hemorrhage. In human patients, higher levels of TGF-β1 within the first 3 days following stroke predicted better outcomes three months into recovery.
Researchers have developed a biodegradable capsule that can administer protein therapy to treat hemophilia B, providing hope for a more accessible and affordable treatment. The oral delivery system contains micro- and nanoparticles that carry the protein therapy and are designed to release it over time, alleviating the burden of inject...
Researchers found a divergent association between alcohol consumption and different types of stroke, with heavy drinking increasing the risk of hemorrhagic stroke. Light to moderate alcohol consumption was associated with a lower risk of ischemic stroke but no effect on hemorrhagic stroke.
A study published in the Canadian Medical Association Journal found that combining dabigatran with two commonly prescribed statins, lovastatin and simvastatin, increases the risk of bleeding. The risk is higher than other statins, suggesting a clinically important drug interaction.
Using statins like lovastatin and simvastatin may increase the risk of bleeding when combined with dabigatran etexilate, a stroke prevention medication. Researchers found an increased risk of bleeding requiring hospital admission or emergency department visits with these statin combinations.
A team of physicians at LSU Health New Orleans has developed a novel technique to identify hidden sources of gastrointestinal bleeding. The method, which combines endoscopy with the administration of antiplatelet or anticoagulant agents, was found to be safe and effective in identifying the source of bleeding in 56% of patients.
Researchers have developed a new biomaterial that can prevent uncontrolled bleeding in patients who cannot form blood clots. The injectable material, known as a shear-thinning biomaterial (STB), is made up of gelatin and nanoparticles and has been shown to be effective in animal models.
A new study found that combining rivaroxaban with single or dual anti-platelet therapy reduces clinically significant bleeding in patients with atrial fibrillation who undergo stenting procedures. The treatment strategy also lowers risks of rehospitalization and death from all causes.
Researchers develop a new therapy that prolongs thrombin production, potentially treating both hemophilia A and B, including those with antibodies against standard therapy. The treatment could also accelerate clot formation in patients with factor V Leiden, offering a more effective and long-acting alternative to current therapies.
Blocking furin protein may offer unexpected benefits for patients with hemophilia A. Gene therapy and protein replacement treatments may be more effective with this approach.
A new clinical trial confirms that general practitioner-prescribed treatments can significantly help women with heavy periods. The trial found that most women avoid surgical interventions and experience similar improvement in period heaviness regardless of treatment type.
Researchers at Emory and Georgia Tech developed a microfluidic testing ground to measure individual platelets' strength by squeezing protein dots together. This could help diagnose bleeding disorders and develop blood thinning drugs.
A Mayo Clinic study found that NOACs dabigatran, rivaroxaban, and apixaban are at least as effective as warfarin in preventing stroke in atrial fibrillation patients. However, apixaban was associated with lower major bleeding rates, while rivaroxaban had a higher risk of serious bleeding.
The Pitt team has received a $2.5 million contract from the US Department of Defense to further develop a retrievable stent for treating life-threatening hemorrhages in servicemen and civilian gunshot victims. The device can be rapidly placed by non-vascular physicians with minimal training, simplifying treatment in emergency situations.
A new antidote, andexanet alfa, has been shown to rapidly reverse anticoagulant effects in patients with acute major bleeding. In the ANNEXA-4 study, andexanet reduced anti-fXa activity by up to 90% within half an hour, resulting in 'excellent or good' hemostasis at 12 hours in most subjects.
The NIPPON study found that shorter dual antiplatelet therapy (DAPT) is comparable to longer DAPT in terms of net adverse clinical and cerebrovascular events. A combination of short DAPT and a newer DES with bioabsorbable coating may minimize thrombotic events and bleeding complications.
A study of over 43,000 patients with atrial fibrillation found that new oral anticoagulants (NOACs) provided similar stroke prevention to warfarin, but caused fewer bleeding incidents. NOACs were associated with a lower risk of intracranial bleeding, particularly when compared to warfarin.
Developed by an antibody that blocks clot formation without triggering bleeding, the new blood thinner could be used to treat patients with heart and vascular diseases. Researchers also created a second antibody to rapidly reverse its effects, addressing safety concerns.
Researchers developed nanoparticles that congregate at injury sites to form blood clots. These particles can cut bleeding time in half and reduce total blood loss, making them a potential game-changer for treating internal bleeding.
Researchers have developed a novel genetically engineered clotting factor that can rapidly reverse bleeding in animal models. The factor, FXaI16L, safely restores blood-clotting ability and significantly reduces bleeding when infused before or during an active bleed.
Smoking is a leading risk factor for subarachnoid hemorrhage in women, with those who smoke up to 30 cigarettes per day facing the greatest danger. Quitting smoking significantly reduces the risk of this condition, making it an essential step in maintaining brain health.
A study found moderate-to-severe gingivitis to be common in pregnant women, particularly among younger mothers. Regular dental care is crucial for maintaining oral health during pregnancy, as gestational age and maternal age were significant factors in gingival bleeding.
A new imaging technique helps identify patients at risk of severe bleeding after stroke treatment by analyzing the extent of blood-brain barrier disruption. This association can inform treating physicians on the risk of bleeding and potentially guide clinical decisions.
A study published in JAMA Neurology found that larger hematoma size and location are associated with an increased risk of dementia after intracerebral hemorrhage. The research also identified educational level, mood symptoms, and white matter disease as risk factors for delayed post-ICH dementia.
A recent NIH-funded study found that standard and intensive blood pressure treatments were equally effective in the emergency treatment of acute intracerebral hemorrhage, a type of stroke caused by bleeding into the brain. After 90 days, the rate of death or severe disability was equal for both groups, at around 38 percent.
Researchers at Penn Vet found that a common blood test may also indicate hypercoagulability in animals. A study of hundreds of dogs found that shortened prothrombin time and activated partial thromboplastin time were associated with clinical signs of hypercoagulability, including clots and suspected pulmonary thromboembolism.
A computerized decision support tool helps physicians and patients make informed decisions about blood thinning treatment to prevent strokes in individuals with atrial fibrillation. The tool, which takes into account patient characteristics and medical therapies, resulted in a significant reduction in deviations from recommended treatm...
The European Stroke Organisation Conference highlighted major clinical trials on treating patients who suffer a stroke caused by bleeding into the brain. Studies found that platelet transfusion may be harmful and is not beneficial for patients taking aspirin. Additionally, tissue plasminogen activator (r-tPA) treatment was shown to red...
A major global study has identified a safer treatment for acute stroke, revealing that a modified dosage of the controversial clot-busting drug rtPA can significantly reduce serious bleeding in the brain while improving survival rates. The trial involved over 3,000 patients in 100 hospitals worldwide and showed promising results.
Researchers presented findings from the SOCRATES trial, which tested ticagrelor against aspirin for reducing further strokes. The study showed that ticagrelor did not significantly reduce second strokes or death. In contrast, a lower dose of intravenous rtPA reduced serious brain bleeding by two-thirds and improved survival rates. Addi...
A study of TAVR patients using different anticoagulation medications found comparable survival and vascular complication rates between men and women. However, a trend was observed that women given bivalirudin experienced less mortality, warranting further investigation.
A retrospective study found that young women undergoing PCI for acute coronary syndrome experience higher rates of adverse cardiovascular events and bleeding risks compared to men. The study highlights the importance of objectively assessing all risk factors when prescribing antiplatelet therapy.
A new study reveals vast differences in treatment recommendations among physicians for brain hemorrhage patients. The variation was found to be influenced by factors such as the physician's specialty and experience with the condition. Researchers recommend that clinicians consider these variations when communicating with families, as i...
A national hospital system reduced bleeding events by 40% for PCI patients using a risk-directed approach and the National Cardiovascular Data Registry's bleeding risk calculator. This resulted in significant cost savings, with estimated reductions of approximately $1 million.
A newly discovered Australian plant species has been named Solanum ossicruentum, based on characteristics of its unripened and mature fruits. The name was chosen from essay submissions by a class of US 7th graders who participated in the research project.
A study published in JAMA Cardiology found that well-managed warfarin therapy is associated with a low risk of complications in patients with atrial fibrillation. The annual incidence of all-cause mortality was 2.19%, and intracranial bleeding rates were 0.44%.
Researchers have developed a potentially life-saving drug therapy called ALM that can reduce internal blood loss by up to 60% in traumatic injuries. The treatment, administered intravenously, has shown promise in treating shock and stabilizing vital organs.
The USPSTF recommends taking low-dose aspirin for primary prevention of cardiovascular disease and colorectal cancer in adults aged 50-69 years with increased risk. Aspirin use can outweigh harms for some patients, including those at high risk for CVD, improving life expectancy and quality of life.
A new biomarker-based tool, 'ABC risk score,' allows for personalized treatment to prevent strokes with minimal bleeding complications. The app is available as a web-based instrument and will soon be available as an app.
Women who underwent uterine fibroid embolization reported improved sexual function, including pain, desire, arousal, and satisfaction. About nine in 10 women also experienced a better overall quality of life, with average scores increasing from 45 to 71 one year after treatment.